High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. - Wikidata - awgldk - TriplyDB

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

http://www.wikidata.org/entity/Q33182232

about

Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer Quercetin-4'-O-β-D-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cells Stimulus-responsive ultrasound contrast agents for clinical imaging: motivations, demonstrations, and future directions.Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells.(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.Bevacizumab and breast cancer: current therapeutic progress and future perspectives Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells.An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.The -1154 G/A VEGF gene polymorphism is associated with the incidence of basal cell carcinoma in patients from northern Poland.Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?Bevacizumab in metastatic breast cancer: when may it be used?Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors Expression of Hypoxia-inducible factor 1-α and vascular endothelial growth factor-C in locally advanced breast cancer patients.CoREST1 promotes tumor formation and tumor stroma interactions in a mouse model of breast cancer.Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.Gene expression and hypoxia in breast cancer.Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.Radiation-Triggered NF-κB Activation is Responsible for the Angiogenic Signaling Pathway and Neovascularization for Breast Cancer Cell Proliferation and Growth.Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer Baseline blood immunological profiling differentiates between Her2-breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response.Antiangiogenic therapies in early-stage breast cancer.Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer.The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.Hinokitiol inhibits vasculogenic mimicry activity of breast cancer stem/progenitor cells through proteasome-mediated degradation of epidermal growth factor receptor.EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression.Green tea catechins inhibit angiogenesis through suppression of STAT3 activation.Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.

P2860

Q24797535-D235F8AF-E56D-4621-9D56-92D40C7DD520 Q28079013-BB275F40-94BD-41BB-82AE-0D345265BB8B Q28480617-201D0B45-E71E-4A35-81B5-D51D78B414C1 Q30395097-3D515888-8DA4-4D4C-85AD-4465ABF0BCEE Q31132489-EAB088B1-9774-4390-A831-9056E171E023 Q33501853-2A7C1D82-ECC9-4B2D-AC2C-E53D72A902F4 Q33589345-EE18D8AE-221E-4867-BCF9-F1017A7CC8D4 Q33590458-F91F1DBE-B7DF-41F0-9B07-1C1B901801B4 Q33640753-567A4F8B-D423-4FEC-98E8-D4623423612C Q33726477-6EA86D64-3D8F-40D8-82FD-76782816A9D3 Q33932531-A16DBD20-0923-4552-B95A-B6A34E52C7B9 Q33935434-1055602E-8B12-455C-AFD3-B872A7FD9C6B Q34080323-6B3733CF-ABBC-4DE4-8CA2-197B141A1CBB Q34085964-CAEE7614-434E-4DB7-9591-F654477A51CB Q34245787-F527A552-0E0E-4CDA-8466-E0CA7DEAA004 Q34258373-775E9E7C-317B-4953-BE96-8FA61C3E5059 Q34613612-41096B80-5B2C-413E-8E4C-9B3FC24AAB3F Q34996947-F5C8A77B-88F9-4B09-BA68-EC43EF5090EE Q35076287-D660D787-6F8A-45B5-8224-E818F685FB1C Q35076351-BCD48BAE-3195-45E1-A73E-4AA5569DDE8D Q35110068-AA7C693A-34CC-41C7-A173-324B63B47E2E Q35179664-E0B5AC96-582F-4DC5-948D-8A370208496F Q35202927-F204677A-7E5E-4C3B-8743-C85C106F77F9 Q35583942-40913BCE-3D81-4AC5-AB74-102ED8C47B03 Q35584239-6A8449C7-FC3D-47FB-BF9A-E0AD87314F25 Q35614451-BAC95DF2-2F40-441C-9D03-6A8E88B8058B Q35628188-088630D7-5221-40DB-9313-C82432669239 Q35671180-28743E1E-453A-41A2-975A-302697F518FC Q36138934-66633297-C82C-4D00-82CA-8575F636406E Q36147155-2BB1AFC8-180E-403F-9EBE-85DD95C51137 Q36307206-6517BA58-A4C0-4985-B3DD-43222594454B Q36318210-D68D622D-2CE7-4158-A181-819333BF1B0E Q36611325-52B5BECC-F100-4EAB-BB0A-AC33CF445085 Q36616962-4572498A-5FDB-43DA-AA99-2575E5D82F19 Q36624140-91ECAC5D-61F8-4C64-9D39-DDD8CBBF0BAA Q36742307-1B57D432-6C5D-4206-ABD6-7C03449DFA1E Q36831607-97D1FE99-AFBE-4CA5-B3FF-9F2D6799F1E5 Q36876370-F4DF3857-4268-4F32-A25A-A716A5C78506 Q36977587-B8D4F524-0903-46CB-BC73-1F6D80506EB6 Q37210542-E3246E06-1177-4B47-A46E-85A4EFA9C718

P2860

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

http://www.wikidata.org/entity/Q33182232

description

2001 nî lūn-bûn

@nan

2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

High tumor levels of vascular ...... apy in advanced breast cancer.

@ast

High tumor levels of vascular ...... apy in advanced breast cancer.

@en

type

label

High tumor levels of vascular ...... apy in advanced breast cancer.

@ast

High tumor levels of vascular ...... apy in advanced breast cancer.

@en

prefLabel

High tumor levels of vascular ...... apy in advanced breast cancer.

@ast

High tumor levels of vascular ...... apy in advanced breast cancer.

@en

P1433

Q33182232-04E315F1-F7DF-4901-826D-A3ECA946BCE4

P1476

Q33182232-D3058F9A-F636-4F41-B414-714DD15D6E50

P2093

Q33182232-081302A8-5027-49CA-A17F-84ADE2FC6496

Q33182232-12B1721D-159C-4296-9BEC-7E4351CB95DC

Q33182232-13947062-3566-4B0C-847D-2B3C1D9D640D

Q33182232-19E63A8A-81C3-4753-9FB1-2971F85A2516

Q33182232-565C3BBE-82AE-4298-98DB-220568BC3365

Q33182232-79DFB42C-E38A-4ADD-AE95-1BE557B79EA9

Q33182232-7DBEDAF5-2F4E-4D15-88DF-1B088EF48644

Q33182232-99113C2A-1732-4D13-A4E6-D3A7DEA9D494

Q33182232-FE5D97D1-2961-4E5B-A5EB-38EE7DDE70BD

P304

Q33182232-857CAC90-489A-44C0-849A-508D1ECD8FF3

P31

Q33182232-57C22BD5-BE6F-449C-88FF-14FF0BAA173B

P407

Q33182232-A7080D74-5E9E-4751-AFA6-5CF872603053

P433

Q33182232-F7838E0F-3FEC-429B-81B1-184085EF0418

P478

Q33182232-1383931E-DB74-44C0-9EC9-80D447E1A92D

P577

Q33182232-E7386ED0-30CB-46D5-849A-BD2E32DC6750

P698

Q33182232-23840691-ED9A-4BC0-8372-C126929A92C6

P921

Q33182232-295FFA3D-ECEB-41A3-BDA3-41326AB690EE

P1433

Cancer Research

P1476

High tumor levels of vascular ...... rapy in advanced breast cancer

@en

P2093

Foekens JA

http://www.w3.org/2001/XMLSchema#string

Geurts-Moespot A

http://www.w3.org/2001/XMLSchema#string

Grebenchtchikov N

http://www.w3.org/2001/XMLSchema#string

Klijn JG

http://www.w3.org/2001/XMLSchema#string

Look MP

http://www.w3.org/2001/XMLSchema#string

Meijer-van Gelder ME

http://www.w3.org/2001/XMLSchema#string

Peters HA

http://www.w3.org/2001/XMLSchema#string

Sweep CG

http://www.w3.org/2001/XMLSchema#string

van der Kwast TH

http://www.w3.org/2001/XMLSchema#string

P304

5407-5414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11454684

http://www.w3.org/2001/XMLSchema#string

P921